Early Detection,
Early Assurance
Patients
The early weeks of pregnancy can be an exciting, but anxious time. Like many expectant mothers, you may want to know the facts about your baby’s risk for chromosomal abnormalities. More »
Health Care Providers
For years, leading ObGyns and maternal fetal medicine specialists have recognized NTD Labs as the innovator in prenatal screening for open neural tube defects and Down syndrome.
More »
NTD Labs has been a leader in the development of prenatal screening tests for over 30 years. The lab's first trimester prenatal screening test for Down syndrome, First Trimester Screen | Fβ , uses a non-invasive method to determine a patient's risk for having a baby with Down syndrome, and trisomy 18 and 13 earlier in the pregnancy than alternative protocols and with higher detection rates and lower false positive rates. It is the only high sensitivity prenatal screen that uses the free Beta hCG biomarker along with PAPP-A and Nuchal Translucency measurement in assessing individual patient risk for a fetus with Down syndrome. With the use of this screen, physicians can provide earlier assurance and earlier answers at a 91% detection rate and a 5% false positive rate (sensitivity increases to a 95% detection rate at a 2% false positive rate when patients undergo a prenatal fetal nasal bone assessment as well).
References 13, 25 (References)